Stefanie is an expert in antibody discovery and early antibody development.

Stefanie joined Ridgeline from iOmx Therapeutics, a German immuno-oncology biotech, where she was a member of the leadership team and led the antibody discovery efforts. Prior to iOmx Stefanie spent 16 years at MorphoSys, building and then heading MorphoSys’ internal discovery group. She was also responsible for the development of antibody platform technologies as well as therapeutic antibody programs.

Stefanie has authored 17 scientific articles and is an inventor on over 60 granted patents. She earned a Ph.D. at the Max-Planck-Institute for Biochemistry in Martinsried.